Moderna (MRNA) has faced both positive and negative developments recently. In positive news, HHS has made plans to pay Moderna $176 million for the production of an mRNA flu vaccine, and the company also received approval from the UK authorities for their commercial mRNA vaccine plant. Similarly,
Moderna has been awarded $590 million by the HHS to produce mRNA vaccines to fight against potential pandemic influenza threats. However, the company also faced an unfavorable decision in an mRNA patent dispute with SK Bioscience. Concerning their financial performance, the company has seen an impressive 11% surge in its share price but was also hit by market volatility leading to a 19% decline in a single week.
Moderna was performing well and making progress with their pandemic preparedness agenda, but doubts about revenue, as hinted by BofA and Bernstein, led to reduced price targets. Despite this turmoil, the company's cash reserves and ongoing clinical trials offer some assurance.
Moderna MRNA News Analytics from Tue, 02 Jul 2024 07:00:00 GMT to Fri, 25 Apr 2025 21:50:14 GMT -
Rating -1
- Innovation 6
- Information 8
- Rumor 5
